Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Jernberg, Emma ^a   Thysell, Elin ^a   Ylitalo, Erik Bovinder ^a   Rudolfsson, Stina ^a   Crnalic, Sead ^a   Widmark, Anders ^a   Bergh, Anders ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450; CYTOCHROME P450 17A1; ENZYME; MESSENGER RNA; OXIDOREDUCTASE; PROTEIN AKR1C2; PROTEIN AKR1C3; PROTEIN HSD17B10; PROTEIN HSD17B6; PROTEIN HSD3B2; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROIDOGENIC ENZYME; UNCLASSIFIED DRUG;

ADRENAL GLAND; ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; NERVE ENDING; OUTCOME ASSESSMENT; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLICING DEFECT; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROIDS;

EID: 84892421933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077407     Document Type: Article

References (36)

1. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, et al. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227.
2. Ryan CJ, Tindall DJ (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29: 3651-3658.
3. Guo Z, Qiu Y (2011) A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 7: 815-822.
4. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209-9216.
5. Crnalic S, Hörnberg E, Wikström P, Lerner UH, Tieva A, et al. (2010) Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr Relat Cancer 17: 885-895.
6. Wang W, Epstein JI (2008) Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 32: 65-71.
7. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, et al. (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2: 995-1003.
8. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.
9. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligandindependent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
10. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
11. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
12. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287: 19736-19749.
13. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448.
14. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
15. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
16. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, et al. (2010) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70: 1256-1264.
17. Crnalic S, Hildingsson C, Wikström P, Bergh A, Löfvenberg R, et al. (2012) Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop 83: 80-86.
18. Crnalic S, Löfvenberg R, Bergh A, Widmark A, Hildingsson C (2012) Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score. Spine (Phila Pa 1976) 37: 2168-2176.
19. Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, et al. (2005) Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11: 4365-4371.
20. Dillard PR, Lin MF, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295: 115-120.
21. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, et al. (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68: 6407-6415.
22. Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8: 73-85.
23. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, et al. (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108: 13728-13733.
24. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, et al. (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71: 1486-1496.
25. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, et al. (1995) Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63: 544-550.
26. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, et al. (2004) The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64: 765-771.
27. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, et al. (1994) Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152: 433-437.
28. Levine AC, Wang JP, Ren M, Eliashvili E, Russell DW, et al. (1996) Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 81: 384-389.
29. Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM (2006) Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol 20: 444-458.
30. Penning TM, Bauman DR, Jin Y, Rizner TL (2007) Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor. Mol Cell Endocrinol 265-266: 77-82.
31. Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, et al. (2012) Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med 18: 1449-1455.
32. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, et al. (2012) Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 72: 6142-6152.
33. Penning TM, Byrns MC (2009) Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 1155: 33-42.
34. Mostaghel E, Nelson PS, Nelson C, Montgomery RB (2010) Intraprostatic steroidogenic enzymes - letter. Cancer Res 70: 8247-8249; author reply 8249-8250.
35. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, et al. (2011) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30: 637-643.
36. Byrns MC, Jin Y, Penning TM (2011) Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J Steroid Biochem Mol Biol 125: 95-104.